HR3826

HR3826, the Expanding Access to Diabetes Self-Management Training Act of 2025, was introduced in the House on June 6, 2025 by Rep. Schrier (D-WA) and referred to the Energy and Commerce and Ways and Means Committees. This is an early-stage authorization bill — it does not appropriate any specific dollar amount. The bill amends the Social Security Act to mandate Medicare coverage of an initial 10 hours of DSMT (available until used) plus 2 hours per year, and prohibits CMS from limiting medically necessary training. It also orders the Center for Medicare and Medicaid Innovation to run a virtual DSMT pilot. The money trail here is indirect: the bill does not authorize a fixed funding pool. Instead, it directs CMS to cover additional DSMT hours under Part B (reimbursement for training services). The cost is borne by the Medicare Trust Fund, increasing per-beneficiary spending on training services. The financial impact on device makers comes through increased patient engagement: patients who receive comprehensive DSMT are more likely to initiate and adhere to CGM and insulin pump therapy. Medicare already covers CGM for all insulin-treated patients, so expanding DSMT expands the addressable patient base for CGM and pump manufacturers who are already Medicare-reimbursed. Structural winners are pure-play CGM manufacturers DexCom ($DXCM) and Abbott ($ABT), whose entire diabetes businesses benefit from expanded Medicare beneficiary engagement. Medtronic ($MDT) benefits as a pump manufacturer, though its diabetes segment is a smaller portion of its total revenue (~12%). Tandem Diabetes ($TNDM) and Insulet ($PODD) are also beneficiaries but are smaller in Medicare pump market share. The virtual DSMT pilot specifically benefits telehealth platforms, though the bill does not name specific vendors. Real market data shows all three tickers trading near 52-week lows: $DXCM at $58.33 (52-week range $54.11–$89.98, -7.12% over 30 days), $ABT at $90.74 (52-week range $90.29–$139.06, -11.62% over 30 days), and $MDT at $79.90 (52-week range $78.91–$106.33, -7.79% over 30 days). The sector-wide pullback (medtech has been weak across the board due to GLP-1 disruption fears, macro uncertainty, and China headwinds) may have oversold the Medicare-specific volume driver that HR3826 represents. Timeline: HR3826 is in Committee referral phase with no scheduled markup. It has a Senate companion (S.1925, referred to Finance Committee) and bipartisan House cosponsors, which improves but does not guarantee passage. The 119th Congress runs through 2026, so committee action and potential floor votes would occur during 2025–2026. Passage probability is moderate — similar diabetes access bills have had difficulty advancing but the bipartisan nature and modest scope (no new funding, only coverage mandate) increase odds.